Trevi Therapeutics
IPO
About
Trevi Therapeutics develops nalbuphine ER for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis and levodopa-induced dyskinesia
Trevi Therapeutics develops nalbuphine ER for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis and levodopa-induced dyskinesia